nonprofit logo

Parker Institute For Cancer Immunotherapy

Learn about this cause: What are the reviews? Is it Legit? Do I like the mission? What is the CEO's salary?

EIN: 473355381 ✦ San francisco, CA ✦ Designated as a 501(c)(3)

Shop smarter and support your favorite cause at the same time! With the Give Freely browser extension, you'll automatically save money with coupons, and partner stores will donate to your chosen charity - at no extra cost to you. Start giving back with a single click. It's safe, free, and spam-free, guaranteed!

Overview

What is Parker Institute For Cancer Immunotherapy?

The Parker Institute for Cancer Immunotherapy (PICI) is a leading nonprofit organization based in San Francisco, California, with a workforce of 92 individuals. Its primary objective is to catalyze the progress of cancer immunotherapy research, collaboration, and discovery, ultimately translating these advances into cures and treatments for patients. PICI conducts its own research and clinical trials while offering its consortium of renowned hospitals and academic research centers shared research resources, such as scientific equipment, consumables, bioinformatics analysis, and a specimen biobank. The institute also funds and supports cancer immunotherapy research within its network. The mission of PICI is to accelerate the development of groundbreaking immune therapies, transforming all cancers into manageable diseases.


Official website here: www.parkerici.org

What are the reviews and ratings of this charity?

Charity Navigator Rating: 92% (Four-Star out of Four Stars)

The Parker Institute for Cancer Immunotherapy has earned a strong Four-Star rating from Charity Navigator, reflecting its high level of accountability and financial health. The organization excels in several key areas, including having a fully independent board and robust financial oversight. Notably, there have been no material diversions of assets, indicating a strong commitment to ethical financial practices.

Strengths of the organization include an impressive program expense ratio of 83.45%, demonstrating that a significant portion of its resources is allocated directly to its mission. Additionally, it has a strong liabilities to assets ratio of 13.90%, showcasing its financial stability. The presence of thorough policies regarding conflict of interest, whistleblower protections, and documentation practices further reinforces its dedication to transparency and governance.

However, there is a limitation noted in its fundraising efficiency ratio, which stands at $0.002. This suggests that while the organization is effective in utilizing its resources for programs, the cost of fundraising efforts may be relatively high. Addressing this aspect could enhance their overall operational efficiency and ability to attract more funding for their missions.


This AI summary has been generated from information found on Charity Navigator.

Is Parker Institute For Cancer Immunotherapy legitimate?

Parker Institute For Cancer Immunotherapy is a legitimate nonprofit organization registered as a 501(c)(3) entity. Parker Institute For Cancer Immunotherapy submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.


Heare are some key statistics you may want to consider:

Executive Compensation: $2,237,353
Professional Fundraising Fees: $0
Other Salaries and Wages: $15,406,447

For more financial information, click here


Official website here: www.parkerici.org

What is the mission statement of Parker Institute For Cancer Immunotherapy?

The Parker Institute for Cancer Immunotherapy (PICI) is dedicated to expediting the development of groundbreaking immune therapies to transform cancer into manageable diseases. Through its own research and clinical trials, as well as collaborations with leading hospitals and academic research centers, PICI fosters advances in cancer immunotherapy. The institute provides its consortium with shared research resources like scientific equipment, consumables, bioinformatics analysis, and a specimen biobank. Moreover, PICI funds and supports cancer immunotherapy research within its network.


Official website here: www.parkerici.org

Who is the CEO of Parker Institute For Cancer Immunotherapy?

Ute Dugan is the Principal Officer of Parker Institute For Cancer Immunotherapy.


Official website here: www.parkerici.org

What is the revenue of Parker Institute For Cancer Immunotherapy?

Parker Institute For Cancer Immunotherapy's revenue in 2022 was $32,769,137.


Official website here: www.parkerici.org

Who are the executives of Parker Institute For Cancer Immunotherapy and what are their salaries?

The average compensation at Parker Institute For Cancer Immunotherapy during 2022 was $191,780. There are 92 employees and 19 volunteers at Parker Institute For Cancer Immunotherapy.


Here are 26 key members and their salaries:


John Connolly Phd (Chief Scientific Officer)
  • Compensation: $854,600
  • Related: $0
  • Other: $34,231
Ute Dugan Md (Chief Medical Officer)
  • Compensation: $751,934
  • Related: $0
  • Other: $43,380
Tarak Mody (Chief Business Officer)
  • Compensation: $586,752
  • Related: $0
  • Other: $43,381
Justin Fairchild (Vp Clinical Dev. Thru 9/30/22)
  • Compensation: $535,136
  • Related: $0
  • Other: $33,360
Shane Corcoran (Senior Vp, Strat. Ops. & Comms)
  • Compensation: $521,356
  • Related: $0
  • Other: $42,581
Lisa Butterfield (Vp Res. & Dev. Thru 7/31/22)
  • Compensation: $525,443
  • Related: $0
  • Other: $29,610
Sara Coblin (Sr Vp Finance & Admin.)
  • Compensation: $522,112
  • Related: $0
  • Other: $31,096
Lacey Padron (Vp Informatics)
  • Compensation: $400,026
  • Related: $0
  • Other: $38,873
Sean N Parker (Chair Of The Board & Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Michael Polansky (Executive Vp & Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Tom Van Loben Sels (Treasurer & Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Jeffrey A Bluestone Phd (Vice Chair & Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Tony Coles Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Eric Esrailian Md Mph (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Scott Gottlieb Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Ben Horowitz (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Jeff Huber (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Bob Hugin (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Reed Jobs (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Joel Marcus (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Bob Nelsen (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Bruce Parker Phd (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Bob Pittman (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Ramy Ibrahim Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Margo Georgiadis (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Susan Dawson (Secretary)
  • Compensation: $0
  • Related: $0
  • Other: $0


Official website here: www.parkerici.org

Where can I find the form 990 for Parker Institute For Cancer Immunotherapy?

Parker Institute For Cancer Immunotherapy's most recent form 990 was submitted in 2022 and can be accessed here.


Official website here: www.parkerici.org

Learn more at the official website: www.parkerici.org

Mission Statement of Parker Institute For Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy (PICI) is a pioneering organization dedicated to revolutionizing cancer treatment through the development of groundbreaking immune therapies. With a mission to transform all cancers into manageable diseases, PICI fosters advances in research, collaboration, and discovery within the realm of cancer immunotherapy.

To achieve this ambitious goal, the Parker Institute engages in its own research and clinical trials while supplying its consortium of prestigious hospitals and academic research centers with vital shared resources. These resources include scientific equipment, consumables, bioinformatics analysis, and a specimen biobank, collectively contributing to the acceleration of immunotherapy research and the eventual translation of these advancements into curative treatments for patients.

Furthermore, PICI extends its support beyond its consortium by funding and assisting cancer immunotherapy research in various spheres, ultimately driving innovation in the field and bringing hope to those battling cancer.

Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!

Impact




October, 2024

The Parker Institute for Cancer Immunotherapy significantly advances cancer immunotherapy research and development. By fostering collaboration among leading hospitals and academic research centers, it enhances the translation of groundbreaking research into effective treatments and cures for patients. The Institute conducts its own research and clinical trials while providing invaluable resources, including scientific equipment, consumables, bioinformatics analysis, and a specimen biobank, to its consortium partners. This multi-faceted approach accelerates the discovery and application of innovative immune therapies, with a mission to transform all cancers into curable diseases.




This information is meant to be a general summary of Parker Institute For Cancer Immunotherapy. Please take the time to review official sources before making any decisions based upon the content provided here.


Financials

This financial information is from Propublica.

Revenue
$32,769,137 (2022)
Expenses
$62,241,652 (2022)
Efficiency

Other financial information:

This information is from the most recently submitted tax form from this organization, which was in 2022.

  • Investment Income: $15,719,892
  • Program Service Revenue: $13,501,237
  • Gross Receipts: $40,446,762

Assets and Liabilities:

  • Total Assets: $307,154,607
  • Total Liabilities: $57,635,216
  • Net Assets: $249,519,391

Want to help this charity, for free? You can click here to learn more about Give Freely

Programs

Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.

RESEARCH STUDY SPONSORSHIP

Revenue

$10,876,237

LICENSE FEES

Revenue

$2,625,000

Organization Details

Founding Year

2015

Principal Officer

Ute Dugan

Main Address

1 LETTERMAN DRIVE D3500, SAN FRANCISCO, CA, 94129

NTEE Category

Code: E12 - Health

If you are a representative of Parker Institute For Cancer Immunotherapy and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.